Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

This is a clinical practice guideline for adult patients with cancer being treated with immune checkpoint inhibitor (ICPi) therapy. The guideline examines how to manage immune-related adverse events (irAEs) in these patients. Adverse events considered include skin, gastrointestinal, lung, endocrine, musculoskeletal, renal, nervous system, hematologic, cardiovascular, and ocular toxicities. Patient and clinician communication, health disparities, and multiple chronic conditions are also discussed.